Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

Journal Article (Journal Article)

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.

Full Text

Published version (via Digital Object Identifier)
Pubmed Central version
Link to Item

Duke Authors

Zhang, Tian

Cited Authors

Hwang, JK; Agarwal, N; Brugarolas, J; Zhang, T

Published Date

January 1, 2021

Published In

Clinical Cancer Research

Volume / Issue

27 / 1

Start / End Page

5 - 7

PubMed ID

33106290

Pubmed Central ID

PMC7785667

Electronic International Standard Serial Number (EISSN)

1557-3265

Digital Object Identifier (DOI)

10.1158/1078-0432.CCR-20-3506

Language

Conference Location

United States

Scholars@Duke